Clinical Trial

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to other places in the body (metastatic). Telotristat ethyl and somatostatin analog therapy may help to control carcinoid syndrome and carcinoid heart disease.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2021-03-18; most recent amendment 2026-03-05.
Status change: Recruiting → Active, Not Recruiting 2024-08-30
Status change: Not Yet Recruiting → Recruiting 2021-08-23
Trial Details
NCT Number NCT04810091
Lead Sponsor M.D. Anderson Cancer Center
Conditions Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
Enrollment 79 participants
Start Date 2021-05-18
Primary Completion 2025-08-31 (estimated)
Study Completion 2026-08-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-09